These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 37626111)

  • 1. Assessment of clinically actionable pharmacogenetic markers to stratify anti-seizure medications.
    Guin D; Hasija Y; Kukreti R
    Pharmacogenomics J; 2023 Nov; 23(6):149-160. PubMed ID: 37626111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of FDA Table of Pharmacogenetic Associations and Clinical Pharmacogenetics Implementation Consortium guidelines.
    Pritchard D; Patel JN; Stephens LE; McLeod HL
    Am J Health Syst Pharm; 2022 Jun; 79(12):993-1005. PubMed ID: 35230418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenomic biomarkers: Interpretation of information included in United States and Japanese drug labels.
    Shimazawa R; Ikeda M
    J Clin Pharm Ther; 2018 Aug; 43(4):500-506. PubMed ID: 29722046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetic information in Swiss drug labels - a systematic analysis.
    Jeiziner C; Suter K; Wernli U; Barbarino JM; Gong L; Whirl-Carrillo M; Klein TE; Szucs TD; Hersberger KE; Meyer Zu Schwabedissen HE
    Pharmacogenomics J; 2021 Aug; 21(4):423-434. PubMed ID: 33070160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenomic biomarkers in drug labels: what do they tell us?
    Tutton R
    Pharmacogenomics; 2014 Feb; 15(3):297-304. PubMed ID: 24533709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating the frequency and the impact of pharmacogenetic alleles in an ancestrally diverse Biobank population.
    Verma SS; Keat K; Li B; Hoffecker G; Risman M; ; Sangkuhl K; Whirl-Carrillo M; Dudek S; Verma A; Klein TE; Ritchie MD; Tuteja S
    J Transl Med; 2022 Nov; 20(1):550. PubMed ID: 36443877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of Pharmacogenetic Information in Food and Drug Administration Drug Labeling and the Table of Pharmacogenetic Associations.
    Cheng CM; So TW; Bubp JL
    Ann Pharmacother; 2021 Oct; 55(10):1185-1194. PubMed ID: 33384014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenomic information in FDA-approved drug labels: Application to pediatric patients.
    Green DJ; Mummaneni P; Kim IW; Oh JM; Pacanowski M; Burckart GJ
    Clin Pharmacol Ther; 2016 Jun; 99(6):622-32. PubMed ID: 26693845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population structure and pharmacogenomic risk stratification in the United States.
    Nagar SD; Conley AB; Jordan IK
    BMC Biol; 2020 Oct; 18(1):140. PubMed ID: 33050895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetic tests to guide drug treatment in depression: Comparison of the available testing kits and clinical trials.
    Fabbri C; Zohar J; Serretti A
    Prog Neuropsychopharmacol Biol Psychiatry; 2018 Aug; 86():36-44. PubMed ID: 29777729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective Review of Pharmacogenetic Testing at an Academic Children's Hospital.
    Roberts TA; Wagner JA; Sandritter T; Black BT; Gaedigk A; Stancil SL
    Clin Transl Sci; 2021 Jan; 14(1):412-421. PubMed ID: 33048453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Investigation of the Knowledge Overlap between Pharmacogenomics and Disease Genetics.
    Li B; Whirl-Carrillo M; Wright MW; Babb L; Rehm HL; Klein TE
    Pac Symp Biocomput; 2022; 27():385-396. PubMed ID: 34890165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic Variation among Pharmacogenes in the Sardinian Population.
    Idda ML; Zoledziewska M; Urru SAM; McInnes G; Bilotta A; Nuvoli V; Lodde V; Orrù S; Schlessinger D; Cucca F; Floris M
    Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fetal pharmacogenomics: A promising addition to complex neonatal care.
    Raymond M; Critchlow E; Rice SM; Wodoslawsky S; Berger SI; Hegde M; Empey PE; Al-Kouatly HB
    Mol Genet Metab; 2022; 137(1-2):140-145. PubMed ID: 36029725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenomic Biomarkers in US FDA-Approved Drug Labels (2000-2020).
    Kim JA; Ceccarelli R; Lu CY
    J Pers Med; 2021 Mar; 11(3):. PubMed ID: 33806453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prescription medications with actionable pharmacogenomic recommendations in Veterans Health Administration patients.
    Maghari S; Gallo T; Rivas S; German A; Nguyen Le MQ; Abbaszadegan H; Zubriski MA; Heise CW; Landas ND
    Pharmacogenomics; 2023 Jun; 24(9):501-508. PubMed ID: 37435738
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet?
    Verbelen M; Weale ME; Lewis CM
    Pharmacogenomics J; 2017 Oct; 17(5):395-402. PubMed ID: 28607506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetic biomarkers for predicting drug response.
    Bank PC; Swen JJ; Guchelaar HJ
    Expert Rev Mol Diagn; 2014 Jul; 14(6):723-35. PubMed ID: 24857685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of population-level pharmacogenetic actionability in Alabama.
    Davis BH; Williams K; Absher D; Korf B; Limdi NA
    Clin Transl Sci; 2021 Nov; 14(6):2327-2338. PubMed ID: 34121327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenomic landscape of Indian population using whole genomes.
    Sahana S; Bhoyar RC; Sivadas A; Jain A; Imran M; Rophina M; Senthivel V; Kumar Diwakar M; Sharma D; Mishra A; Sivasubbu S; Scaria V
    Clin Transl Sci; 2022 Apr; 15(4):866-877. PubMed ID: 35338580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.